


CLAIMS

What is claimed is:

- 5 1. A method of treating rheumatoid arthritis, comprising administering to a patient a therapeutically effective dose of a TLR7/8 inhibitor or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective dose of a TNF α inhibitor.

2. The method according to claim 1 wherein said TLR7 inhibitor is:



or a pharmaceutically acceptable salt thereof.

3. The method according to claim 1 wherein said TNF α inhibitor is etanercept or a biosimilar thereof.
- 15 4. The method according to claim 1 wherein said TNF α inhibitor is infliximab or a biosimilar thereof.
5. The method according to claim 1 wherein said TNF α inhibitor is certolizumab or a
- 20 biosimilar thereof.
6. The method according to claim 1 wherein said TNF α inhibitor is golimumab or a biosimilar thereof.
7. The method according to claim 1 wherein said TNF α inhibitor is adalimumab or a biosimilar thereof.
8. The method according to Claim 1, wherein said therapeutically effective dose of said TLR7 inhibitor is from 0.1 to 100 mg per day.

9. The method according to claim 1 wherein said TLR7/8 inhibitor and said TNF α inhibitor are administered concurrently.
- 5 10. The method according to claim 1 wherein said TLR7/8 inhibitor and said TNF α inhibitor are administered sequentially.
11. The method according to claim 1 wherein said TLR7/8 inhibitor is administered prior to administration of said TNF α inhibitor.
- 10 12. The method according to claim 1 wherein said TNF α inhibitor is administered prior to administration of said TLR7/8 inhibitor.
13. A polypeptide comprising amino acid residues 18-486 of SEQ ID NO:1.
- 15 14. The polypeptide of claim 13, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:1.